Jun. 21 at 2:35 AM
Where’s your favorite penny or small cap biotech ranked? Here’s Grok’s take. Do you agree?
Updated Ranking (based on market cap, pipeline, commercial status, and recent performance):
1.
$SNDX (
$882M) - Two FDA-approved drugs (Revuforj, Niktimvo), commercial-stage, strong pipeline, higher stability.
2.
$ARQT (
$1.60B) - Commercial-stage, approved product (Zoryve), strong market cap.
3.
$CRMD (
$1.01B) - Late-stage pipeline, no approved products yet, but strong market cap and momentum.
4.
$NUVB (
$616M) - Newly commercial-stage with Ibtrozi, high response rates (90% in TKI-naïve patients), but stock volatility and post-marketing trial costs temper upside.
5.
$BNTC (
$433M) - Early-stage gene therapy, high potential but pre-commercial.
6. CADL (
$257M) - Clinical-stage, oncology focus, higher risk.
7. MNPR (
$205M) - Clinical-stage, recent licensing deal boosts potential.
8. PRME (
$192M) - Early-stage, gene-editing, speculative.
9. HUMA (
$374M) - Regenerative medicine.
